Cancer Therapy - Market Share Analysis, Industry Trends & Statistics, Growth Forecasts (2026-2031)

The cancer therapy market size was valued at USD 245.18 billion in 2025 and is estimated to grow from USD 269.55 billion in 2026 to reach USD 446.89 billion by 2031, at a CAGR of 10.64% during the forecast period (2026-2031). This report is Segmented by Therapy Type (Chemotherapy, Targeted Therapy, and More), Cancer Type (Blood, Breast, Prostate, and More), Route of Administration (Intravenous, and More), End User (Hospitals, and More), and Geography (North America, Europe, Asia-Pacific, Middle East and Africa, South America). Market Forecasts are Provided in Terms of Value (USD).

Global Cancer Therapy Market Trends and Insights

Rising Global Cancer Incidence & Aging Population

Worldwide, people aged 65 and older account for most new cancer diagnoses, and health agencies now register oncology as a top cause of urban mortality in multiple regions. Longer lifespans coupled with cumulative exposures to tobacco, ultraviolet radiation, and industrial pollutants ensure persistently high therapy volumes across numerous lines of treatment. National cancer centers in East Asia forecast marked growth in incident cases through 2035, prompting investments in regional oncology hubs. Direct care costs already consume a rising share of health budgets, displacing preventive programs and straining insurance solvency. Hospital systems are scaling their infusion capacity and recruiting oncology specialists to accommodate the influx of patients.

Advances in Immunotherapy and Targeted Therapies

Checkpoint inhibitors, bispecific T-cell engagers, and antibody-drug conjugates have redefined survival benchmarks across tumor types, earning multiple accelerated approvals in the last five years. Bispecific antibodies for multiple myeloma and relapsed lymphoma show durable progression-free survival in heavily pretreated populations. HER2-low breast cancer approvals broaden eligibility to patients previously deemed HER2-negative, reshaping treatment algorithms. KRAS G12C inhibitors, combined with checkpoint blockade, are outperforming chemotherapy in pivotal trials, creating new sequencing challenges for clinicians. The complexity of regimen selection is driving the adoption of clinical decision-support tools that integrate real-world evidence.

High Treatment Costs and Financial Toxicity

Studies show patients facing elevated out-of-pocket expenses are more likely to discontinue oral targeted therapies prematurely, directly reducing overall survival. U.S. CAR-T infusion courses incur total charges exceeding USD 400,000, even for insured patients, encompassing hospital stays, ancillary care, and lost wages. Major assistance foundations report record application volumes yet must cap enrollments as funding lags demand. Payers respond with step-therapy prerequisites, delaying access to novel regimens and compounding disease burden. Policymakers debate co-payment caps to prevent household asset depletion.

Other drivers and restraints analyzed in the detailed report include:

• Growing Adoption of Precision Oncology and Biomarker Testing
• Increasing Healthcare Expenditure and Access in Emerging Markets
• Stringent Regulatory Approval Processes and Clinical Trial Complexity

Segment Analysis

Cell and gene therapy growth at a 12.50% CAGR through 2031 underscores a structural shift away from cytotoxic drugs. Allogeneic CAR-T platforms offer off-the-shelf convenience, trimming manufacturing timelines from weeks to days. Targeted therapy accounted for 37.21% of 2025 revenue, but upcoming biosimilars are expected to erode price points as exclusivities lapse. Checkpoint inhibitors penetrate adjuvant settings, tripling eligible patient pools. Chemotherapy remains pivotal in hematologic malignancies and as a combination backbone, though first-line use in solid tumors is declining. Hormonal therapy sustains favorable toxicity profiles for receptor-positive cancers, enhanced by CDK4/6 inhibitors that extend progression-free survival past 30 months. Bispecific T-cell engagers demonstrate robust response rates in late-line myeloma, while antibody-drug conjugates with novel payloads enlarge responder subsets. The cancer therapy market size for cell and gene therapy is forecast to narrow the gap with targeted agents by 2031 materially. Biosimilars incentivize manufacturers to adopt innovative payload conjugation strategies, thereby preserving premium pricing despite intensifying competition.

Second-generation gene-edited platforms integrate hypoimmune features to evade host rejection, potentially reducing post-infusion cytokine release. Manufacturing scale-out in Singapore and China expands vector supply, tempering historical bottlenecks. Portfolio rationalization among large caps accelerates licensing deals for mid-stage assets in KRAS-mutant malignancies, often surpassing USD 1 billion upfront. Venture investment in oncology AI start-ups supports computational protein design, generating clinically viable candidates more quickly than traditional methods. As new entrants proliferate, the cancer therapy market witnesses a more democratized innovation landscape that challenges historical monopoly dynamics. Investors, therefore, track comparative durability of responses to gauge eventual adoption curves.

Breast cancer retained 18.23% of 2025 revenue as HER2-directed regimens and CDK4/6 inhibitors entrench in earlier-line protocols.

Label expansions for checkpoint inhibitors into neoadjuvant lung settings extend treatment duration, compounding revenue streams. Combination regimens pairing KRAS inhibitors with immunotherapy offer additive benefit, pending final survival analyses. Radioligand therapy trials in earlier prostate cancer lines hint at future label growth. Basket trial successes in NTRK and RET alterations illustrate the potential of tumor-agnostic pathways to unlock cross-histology revenue with limited patient numbers. Market watchers observe whether pancreatic tumor microenvironment modulation strategies translate preclinical promise into survival gains.

Complete Report Scope:

• By Therapy Type
  • Chemotherapy
  • Targeted Therapy
  • Immunotherapy
  • Hormonal Therapy
  • Other Treatment Types
• By Cancer Type
  • Blood Cancer
  • Breast Cancer
  • Prostate Cancer
  • Gastrointestinal Cancer
  • Gynecologic Cancer
  • Respiratory/Lung Cancer
  • Other Cancer Types
• By Route of Administration
  • Intravenous
  • Oral
  • Subcutaneous
  • Intratumoral
• By End User
  • Hospitals
  • Specialty Clinics
  • Cancer And Radiation Therapy Centers
  • Homecare Settings
• Geography
  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • Germany
    • United Kingdom
    • France
    • Italy
    • Spain
    • Rest Of Europe
  • Asia-Pacific
    • China
    • Japan
    • India
    • South Korea
    • Australia
    • Rest Of Asia-Pacific
  • Middle-East And Africa
    • GCC
    • South Africa
    • Rest Of Middle East And Africa
  • South America
    • Brazil
    • Argentina
    • Rest Of South America

Geography Analysis

North America retained 43.23% share in 2025, supported by the world’s highest per-capita oncology spend and a critical mass of research institutions. U.S. legislation capped annual out-of-pocket drug costs for Medicare beneficiaries, promising improved adherence for millions on oral regimens. Canada’s national alliance negotiated confidential rebates on novel biologics, narrowing reimbursement delays. Digital infrastructure supports the collection of extensive real-world evidence, informing value-based contracts.

Europe advances at a high single-digit CAGR through 2031 as outcome-based agreements spread. Germany and the UK tie payment for CAR-T therapies to progression-free survival, shifting risk to manufacturers. The European Medicines Agency pursues rolling reviews to shorten approval cycles for pandemic-delayed dossiers. Biosimilar penetration erodes antibody price points, funding coverage for newer modalities. Central re-evaluation committees periodically reassess comparative therapeutic benefit, modifying prices under health technology assessment frameworks.

The Asia-Pacific region grows fastest, at an 11.20% CAGR, because China adds dozens of therapies to the national reimbursement list at negotiated discounts below Western prices.

Latin America experiences double-digit growth as Brazil embraces biosimilars and Argentina streamlines expedited review pathways. Cross-border clinical trial participation gives patients earlier access while building local site capabilities. Middle Eastern Gulf states invest in integrated cancer campuses staffed by international experts. Africa experiences modest expansion, with donor agencies funding the installation of radiotherapy facilities in urban hubs. Collectively, divergent growth curves underscore the heterogeneous evolution of the cancer therapy market across continents.

List of Companies Covered in this Report:

• Abbvie
• Amgen
• Astellas Pharma
• AstraZeneca
• BeiGene Ltd.
• Bristol-Myers Squibb
• Eli Lilly and Company
• Exelixis, Inc.
• Roche
• Gilead Sciences
• GlaxoSmithKline
• Johnson & Johnson Services Inc. (Janssen)
• Merck
• Novartis
• Pfizer
• Regeneron Pharmaceuticals
• Seagen
• Takeda Pharmaceuticals

Additional Benefits:

• The market estimate (ME) sheet in Excel format
• 3 months of analyst support